KDM1A and schistosomiasis: As part of a continuing effort of several different investigators to identify epigenetic modifications as therapeutic targets to control schistosomiasis, a recent paper published during our study also identified S. mansoni LSD1 (SmLSD1) as an additional promising drug candidate [17].